XERS Stock Summary and Trading Ideas (Xeris Biopharma Holdings | NASDAQ:XERS)

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Xeris Biopharma Holdings trades on the NASDAQ stock market under the symbol XERS.

As of January 9, 2026, XERS stock price declined to $7.93 with 2,472,885 million shares trading.

XERS has a beta of 0.99, meaning it tends to be less sensitive to market movements. XERS has a correlation of 0.08 to the broad based SPY ETF.

XERS has a market cap of $1.32 billion. This is considered a Small Cap stock.

Last quarter Xeris Biopharma Holdings reported $74 million in Revenue and $.00 earnings per share. This beat revenue expectation by $124,998 and missed earnings estimates by -$.01.

In the last 3 years, XERS traded as high as $10.08 and as low as $1.06.

The top ETF exchange traded funds that XERS belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.

XERS has outperformed the market in the last year with a price return of +136.0% while the SPY ETF gained +19.0%. However, in the short term, XERS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -3.3% vs +3.4% return in SPY. But in the last 2 weeks, XERS shares have fared better than the market returning +10.0% compared to SPY +0.5%.

XERS support price is $7.83 and resistance is $8.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XERS shares will trade within this expected range on the day.